The trial recruited 101 EGFR-mutant NSCLC patients who developed resistance to first/second generation TKIs or osimertinib, or harbored EGFR ex20ins with disease progression on chemotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.